Self-Reported Resilience During the COVID-19 Pandemic

The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study is supported by NHLBICollaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS) grant No.OT2HL156812, with cofunding from the National Institute of Neurological Disorders and Stroke (NINDS) and theNational Institute on Aging (NIA). The Atherosclerosis Risk in Communities Study has been funded in whole or inpart by the NHLBI, National Institutes of Health (NIH), and US Department of Health and Human Services, undercontract No. 75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, and75N92022D00005. Neurocognitive data are collected under grant No. U01 2U01HL096812, 2U01HL096814,2U01HL096899, 2U01HL096902, and 2U01HL096917 from the NHLBI, the NINDS, the NIA, and the NationalInstitute on Deafness and Other Communication Disorders. Ancillary studies funded additional data elements. TheBlood Pressure and Cognition Study is supported by the NINDS (grant No. R01 NS102715). The Coronary ArteryRisk Development in Young Adults Study is supported by contract No. 75N92023D00002, 75N92023D00003,75N92023D00004, 75N92023D00005, and 75N92023D00006 from the NHLBI. The Genetic Epidemiology ofCOPD (COPDGene) Study was supported by award No. U01 HL089897 and U01 HL089856 from the NHLBI.COPDGene is also supported by the COPD Foundation through contributions made to an industry advisory boardcomprised of AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis International, Pfizer,Siemens, and Sunovion Pharmaceuticals. The Framingham Heart Study has received support from the NHLBI(grant No. N01-HC-25195, contract No. HHSN268201500001I, and grant No. 75N92019D00031). The HispanicCommunity Health Study/Study of Latinos (HCHS/SOL) is a collaborative study supported by contracts between the NHLBI and the University of North Carolina (contract No. HHSN268201300001I/N01-HC-65233), theUniversity of Miami (contract No. HHSN268201300004I/N01-HC-65234), Albert Einstein College of Medicine(contract No. HHSN268201300002I/N01-HC-65235), the University of Illinois at Chicago (contract No.HHSN268201300003I/N01-HC-65236 [Northwestern University]), and San Diego State University (contract No.HHSN268201300005I/N01-HC-65237). The following institutes, centers, or offices have contributed to theHCHS/SOL through a transfer of funds to the NHLBI: the National Institute on Minority Health and HealthDisparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental andCraniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the NINDS, andNIH Office of Dietary Supplements. The Jackson Heart Study is supported by and conducted in collaboration withJackson State University (contract No. HHSN268201800013I), Tougaloo College (contract No.HHSN268201800014I), the Mississippi State Department of Health (contract No. HHSN268201800015I), theUniversity of Mississippi Medical Center (contract No. HHSN268201800010I, HHSN268201800011I, andHHSN268201800012I), the NHLBI, and the National Institute on Minority Health and Health Disparities. TheMediators of Atherosclerosis in South Asians Living in America (MASALA) Study was supported by grant No.R01HL093009 from the NHLBI, the National Center for Research Resources, and the National Center forAdvancing Translational Sciences, and NIH, through University of California, San Francisco-Clinical andTranslational Science Institute grant No. UL1RR024131. The Multi-Ethnic Study of Atherosclerosis (MESA) and theMESA SNP Health Association Resource (SHARe) are conducted and supported by the NHLBI in collaboration withthe MESA investigators. Support for MESA is provided by grants and contracts from the NHLBI (grant/contractNo. 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160,75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163,75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167,N01-HC-95168, N01-HC-95169, R01-HL077612, R01-HL093081, R01-HL130506, R01-HL127028, R01-HL127659,R01-HL098433, R01-HL101250, and R01-HL135009); NIA (grant No. R01-AG058969); and National Center forAdvancing Translational Sciences (grant No. UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420). Funding forSHARe genotyping was provided by NHLBI contract No. N02-HL-64278. This publication was developed underScience to Achieve Results (STAR) research assistance agreement No. RD831697 (MESA Air) and RD-83830001(MESA Air Next Stage), awarded by the Environmental Protection Agency. Whole-genome sequencing for theTrans-Omics in Precision Medicine (TOPMed) Program was supported by the NHLBI. Whole-genome sequencingfor the MESA component of the TOPMed Study (Database of Genotypes and Phenotypes accession No.phs001416.v1.p1) was performed at the Broad Institute of Massachusetts Institute of Technology and Harvard(grant No. 3U54HG003067-13S1). Centralized read mapping and genotype calling, along with variant qualitymetrics and filtering, were provided by the TOPMed Informatics Research Center (grant No. 3R01HL-117626-02S1and contract No. HHSN268201800002I) (Broad RNA Seq, Proteomics HHSN268201600034I, UW RNA SeqHHSN268201600032I, USC DNA Methylation HHSN268201600034I, Broad MetabolomicsHHSN268201600038I). Phenotype harmonization, data management, sample-identity quality control, andgeneral study coordination were provided by the TOPMed Data Coordinating Center (grant No. 3R01HL-120393and U01HL-120393 and contract s No.HHSN268180001I). The provision of genotyping data was supported in partby the National Center for Advancing Translational Sciences, Clinical and Translational Science Institute grant No.UL1TR001881, and NIDDK Diabetes Research Center grant No. DK063491 to the Southern California DiabetesEndocrinology Research Center. The NHLBI Pooled Cohorts Study was supported by grant No. R21HL153700,K23HL130627, R21HL129924, and R21HL121457 from the NIH/NHLBI. The Northern Manhattan Study wassupported by grant No. R01 NS29993 and R01NS48134 from the NINDS and grant R01 AG066162 from the NIA.The Prevent Pulmonary Fibrosis cohort study was established in 2000 and has been supported by NIH (award No.Z01-ES101947, R01-HL095393, RC2-HL1011715, R21/33-HL120770, R01-HL097163, Z01-HL134585, UH2/3-HL123442, P01-HL092870, and UG3/UH3-HL151865) and by the Department of Defense (grant No. W81XWH-17-1-0597). The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study is supported by cooperativeagreement No. U01 NS041588, cofunded by the NINDS and the NIA. Research by the principal and co-principalinvestigators of the Severe Asthma Research Program was funded by the NIH/NHLBI (grant No. U10 HL109164,U10 HL109257, U10 HL109146, U10 HL109172, U10 HL109250, U10 HL109168, U10 HL109152, and U10HL109086). Additional support was provided through industry partnerships with the following companies:AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, MedImmune, Novartis, RegeneronPharmaceuticals, Sanofi, and Teva Pharmaceuticals USA. Spirometers used in Severe Asthma Research Program IIIwere provided by nSpire Health. The Subpopulations and Intermediate Outcome Measures in COPD Study(SPIROMICS) has been funded by contracts with the NIH/NHLBI (contract No. HHSN268200900013C,HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C,HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C) and grants from the NIH/NHLBI(grant No. U01 HL137880 and U24 HL141762) and supplemented through contributions made to the Foundationfor the NIH and the COPD Foundation by AstraZeneca, MedImmune, Bayer, Bellerophon Therapeutics, BoehringerIngelheim, Chiesi Farmaceutici, the Forest Research Institute, GSK, Grifols Therapeutics, Ikaria, Novartis, Nycomed Pharma, ProterixBio, Regeneron, Sanofi, Sunovion, Takeda Pharmaceutical, Theravance Biopharma, and Mylan.The Strong Heart Study has been funded in whole or in part by the NHLBI (contract No. 75N92019D00027,75N92019D00028, 75N92019D00029, and 75N92019D00030). The Strong Heart Study was previouslysupported by research grant No. R01HL109315, R01HL109301, R01HL109284, R01HL109282, and R01HL109319and cooperative agreement No. U01HL41642, U01HL41652, U01HL41654, U01HL65520, and U01HL65521.